You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

~ Buy the VABOMERE (meropenem; vaborbactam) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VABOMERE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for vabomere

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02166476 ↗ Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Completed Department of Health and Human Services Phase 3 2014-11-20 Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗ Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Completed Melinta Therapeutics, Inc. Phase 3 2014-11-20 Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗ Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Completed Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) Phase 3 2014-11-20 Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02168946 ↗ Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed Department of Health and Human Services Phase 3 2014-07-01 Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗ Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) Phase 3 2014-07-01 Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗ Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) Phase 3 2014-07-01 Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02687906 ↗ Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections Recruiting Department of Health and Human Services Phase 1 2016-07-01 A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for vabomere

Condition Name

Condition Name for vabomere
Intervention Trials
Acute Pyelonephritis 2
Urinary Tract Infection Complicated 2
Ventilator-associated Bacterial Pneumonia 1
Abdominal Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for vabomere
Intervention Trials
Infections 3
Infection 3
Urinary Tract Infections 2
Pyelonephritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for vabomere

Trials by Country

Trials by Country for vabomere
Location Trials
United States 28
Brazil 4
Greece 2
Spain 2
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for vabomere
Location Trials
New Jersey 3
Illinois 3
Ohio 2
New York 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for vabomere

Clinical Trial Phase

Clinical Trial Phase for vabomere
Clinical Trial Phase Trials
Phase 3 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for vabomere
Clinical Trial Phase Trials
Completed 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for vabomere

Sponsor Name

Sponsor Name for vabomere
Sponsor Trials
Department of Health and Human Services 3
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) 3
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for vabomere
Sponsor Trials
Industry 7
U.S. Fed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.